Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Sagimet Biosciences Inc.NASDAQ: SGMT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $10.65M (cash outflow) fell 41.4% year over year, behind the -23.8% change in trailing-twelve-month net income. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at +18.7% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$38.99M (-23.6%) for the fiscal year ending Dec 2026, a slowdown from the +12.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.65M+11.3% QoQ
Last fiscal yearDec 2025
-$51.04M+12.0% YoY
LTMMar 2026
-$43.51M-23.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.4%+28.4%+69.8 pp
1 year+12.0%-23.6%-35.6 pp
3-year CAGR+18.7%+2.0%-16.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(51.04M) USD
Year-over-year change
-12.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SGMT compares with its peers on the latest reported figures

  • SGMT's LTM Mar 2026 net income of $43.51M is the 10th largest of the 11 companies compared; the peer median is $78.05M.
  • Its year-over-year change of -23.8% is the 9th highest of 11, against a peer median of +14.0%.
  • Over three fiscal years its annual growth of +18.7% compares with a peer median of +11.0%.
SGMT Competitors Peer median
Net Income for SGMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M +21.5%+11.0%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$166.12M -770.3%+15.0%2895.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M +25.7%+50.6%4840.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M +15.4%—173.5%
ZURAZura Bio LimitedLTM Mar 2026$77.43M +24.7%+35.9%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
IMRXImmuneering CorporationLTM Mar 2026$54.44M -11.9%+3.5%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M +12.6%+8.9%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$43.51M -23.8%+18.7%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$6.38M -84.0%-59.6%9.0%
Peer median (excluding SGMT) $78.05M+14.0%+11.0%293.2%

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Depreciation & Amortization0130K000
Deferred Income Tax00000
Stock-Based Compensation1.9M1.88M4.99M5.29M6.45M
Change in Working Capital(55K)4.21M(978K)(1.05M)(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables00120K(907K)929K
Other Working Capital(55K)4.21M(1.1M)(141K)(1.98M)
Other Non-Cash Items883K(215K)98K(1.11M)(8K)
Operating Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments0(41.45M)(19.62M)(108.09M)(106.86M)
Sales of Investments09.44M32.2M46.4M111.42M
Other Investing Activities00000
Investing Cash Flow0(32.01M)12.58M(61.68M)4.56M
Debt Repayment00000
Common Stock Issued012K89.68M105.75M275K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.07M)(85K)(3.51M)(931K)0
Financing Cash Flow9.74M(73K)86.17M104.82M275K
Effect of Forex Changes00000
Net Change in Cash(11.97M)(56.57M)74.98M701K(40.82M)
Free Cash Flow(21.71M)(24.49M)(23.77M)(42.44M)(45.65M)

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.